Biofrontera Delivers $41.7M Revenue with 10% Ameluz Volume Growth
Biofrontera reported record 2025 revenue of $41.7 million driven by a 10% increase in Ameluz unit volumes and opening over 150 new accounts. The company acquired U.S. rights and patents for Ameluz and RhodoLED, shifted to a 12–15% royalty model and forecasts 80–85% gross margins in 2026.
1. Record Annual Revenue and Commercial Growth
Biofrontera achieved record 2025 revenue of $41.7 million, led by a 10% increase in Ameluz unit volumes. The company opened over 150 new accounts and reduced customer churn to its lowest level since 2021 through data-driven targeting and an inside sales pilot.
2. U.S. Rights Acquisition and IP Defense
In December 2025, Biofrontera acquired all U.S. rights, patents and manufacturing contracts for Ameluz and RhodoLED, securing full regulatory control. A favorable PTAB decision against Sun Pharma further strengthened its intellectual property protections in dermatology.
3. Improved Cost Structure and Margin Outlook
Replacing a 25–35% transfer pricing model with a 12–15% royalty-based earn-out significantly enhanced Biofrontera’s gross margin profile. Management forecasts stable 80–85% gross margins for 2026 and aims to reach cash flow breakeven through disciplined expense management.
4. Clinical Pipeline and Funding Milestones
Biofrontera targets a PDUFA action date of September 28, 2026 for expanded Ameluz indications and plans a supplemental NDA filing in 2026 for actinic keratosis. The company divested the Xepi license for $3 million upfront, secured $11 million in Series C funding, and has Phase III acne discussions planned.